Skip to main content
SpringerLink
Log in

How quality of life data contribute to our understanding of cancer patients' experiences? A study of patients with lung cancer

  • Published:
Quality of Life Research Aims and scope Submit manuscript

Abstract

A prospective study was conducted to measure quality of life in newly diagnosed lung cancer patients attending a chest clinic in a large teaching and district general hospital in a geographically defined area (northern sector of Glasgow, Scotland). Quality of life was assessed at two points in time, pre-diagnosis (baseline) and 3 months after diagnosis (follow-up) using three standard measures; the Nottingham Health Profile (NHP); the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), and its lung cancer supplement (QLQ-LC13). Out of 133 lung cancer patients diagnosed during the study period, 129 patients (97%) were interviewed pre-diagnosis. Of these, only 63% of the patients had an active treatment. Ninety-six patients were alive at follow-up, of whom 82 patients were re-interviewed. Thus, only 82 patients who had complete data were used in the analysis. Comparing patients' pre-diagnosis and follow-up scores on the NHP, only sleep difficulties improved slightly. Patients reported increased perceived health problems of all other characteristics studied (energy, p = 0.0004; physical mobility, p = 0.0008). Similar results were observed on the EORTC questionnaires indicating that patients' functioning and global quality of life had decreased. The only significant improvement after 3 months was seen in patients' cough (p = 0.006). There were marked increases in hair loss (p > 0.0001), constipation (p = 0.007), and sore mouth (p = 0.0004). The findings suggest that patient-centred variables should receive sufficient consideration in the treatment of lung cancer. The study results clearly indicate that information on quality of life contributes to our understanding of patients' experiences of their cancer treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. International Association of Cancer Registries. Cancer incidence, mortality and prevalence world-wide (2000 estimates). www-dep.iarc.fr/globocan/globocan.html. (accessed 4 February 2002).

  2. Carney DN. Chemotherapy in the management of patients with inoperable non-small cell lung cancer. Semin Oncol 1996; 23(Suppl 16): 71–75.

    Google Scholar 

  3. Tatcher N, Hopwood P, Anderson H. Improving quality of life in patients with non-small cell lung cancer: Research experience with gemcitabine. Eur J Cancer 1997; 33(Suppl 1): 8–11.

    Google Scholar 

  4. Stephens RJ, Hopwood P, Girling DJ, Machin D. Randomized trials with quality of life endpoints: Are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? Qual Life Res 1997; 6: 225–236.

    Google Scholar 

  5. Giaccone G, Splinter TA, Debruyane C, et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1998; 16: 2133–2141.

    Google Scholar 

  6. Souhami RL, Spiro SG, Rudd RM, et al. Five-day oral etoposide treatment for advanced small cell lung cancer: Randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 1997; 89: 577–580.

    Google Scholar 

  7. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: Descriptive study based on scripted interviews. Br Med J 1998; 317: 771–775.

    Google Scholar 

  8. Montazeri A, Gillis CR, McEwen J. Quality of life in patients with lung cancer. A review of literature from 1970-1995. Chest 1998; 113: 467–481.

    Google Scholar 

  9. Joss RA, Alberto P, Hurny C, et al. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomised phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Ann Oncol 1995; 6: 41–48.

    Google Scholar 

  10. Joss RA, Bacchi M, Hurny C, et al. Early versus late alternating chemotherapy in small-cell lung cancer. Ann Oncol 1995; 6: 157–166.

    Google Scholar 

  11. Helsing M, Bergman B, Thaning L, Hero U. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Eur J Cancer 1998; 34: 1036–1044.

    Google Scholar 

  12. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 1999; 91: 66–72.

    Google Scholar 

  13. Ganz PA, Figlin RA, Haskell CM, La Soto N, Siau J. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does treatment make a difference? Cancer 1989; 63: 1271–1278.

    Google Scholar 

  14. Gower NH, Rudd RM, Ruiz de Elvira MCR, et al. Assessment of quality of life using daily diary card in a randomised trial of chemotherapy in small-cell lung cancer. Ann Oncol 1995; 6: 575–580.

    Google Scholar 

  15. Kaasa S, Mastekaasa A, Thorud E. Toxicity, physical function, and everyday activity reported by patients with inoperable non-small cell lung cancer in a randomised trial: Chemotherapy versus radiotherapy. Acta Oncol 1988; 27: 343–349.

    Google Scholar 

  16. Sarna L. Women with lung cancer: Impact on quality of life. Qual Life Res 1993; 2: 13–22.

    Google Scholar 

  17. Hunt SM, Mckenna SP, McEwen J. The Nottingham Health Profile User's Manual. Manchester: Galen Research, 1993.

    Google Scholar 

  18. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organisation for Research and Treatment of Cancer QLQ-C-30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–376.

    Google Scholar 

  19. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 1994; 30A: 635–642.

    Google Scholar 

  20. Zubrod CG, Scheiderman MA, Frei E. Appraisal of methods for the study of chemotherapy in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chro Dis 1960; 11: 7–33.

    Google Scholar 

  21. Carstairs V, Morris R. Deprivation and Health in Scotland. Aberdeen: Aberdeen University Press, 1991.

    Google Scholar 

  22. Swinscow TDV. Statistics at Square One. London: British Medical Association, 1993.

    Google Scholar 

  23. Everitt BS. The Cambridge Dictionary of Statistics in the Medical Sciences. Cambridge: Cambridge University Press, 1995, 31–32.

    Google Scholar 

  24. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989; 27(Suppl 3): 178–189.

    Google Scholar 

  25. Thongprasert S, Sanguanmitra P, Juthapan W, Clinch J. Relationship between quality of life and clinical outcomes in advanced non small cell lung cancer: Best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 1999; 24: 17–24.

    Google Scholar 

  26. Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer: A randomised trial with quality of life as the primary outcome. Br J Cancer 2000; 83: 447–453.

    Google Scholar 

  27. Hopwood P. Quality of life assessment in chemotherapy trials for non-small cell lung cancer: Are theory and practice significantly different? Semin Oncol 1996; 23(Suppl 10) 60–64.

    Google Scholar 

  28. Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions. Clin Cancer Res 1998; 4: 1087–1100.

    Google Scholar 

  29. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life. J Clin Oncol 1999; 17: 3188–3194.

    Google Scholar 

  30. Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support. J Clin Oncol 2000; 18: 395–404.

    Google Scholar 

  31. Harpole LH, Nolte KC, D'Amico TA, Crawford NJ, Harpole DH. Assessing lung cancer patient outcomes at point of service. Proc Am Soc Clin Oncol 2001: 20: 2817 (abstract).

    Google Scholar 

  32. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol 1997; 15: 2996–3018.

    Google Scholar 

  33. Simmonds P. Managing patients with lung cancer. Br Med J 1999; 319: 527–528.

    Google Scholar 

  34. Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States. Cancer 1999; 86: 1867–1876.

    Google Scholar 

  35. Choy H, Shyr Y, Cmelak AJ, Mohr PJ, Johnson DH. Patterns of practice survey for non-small cell lung carcinoma in the US. Cancer 2000; 88: 1336–1346.

    Google Scholar 

  36. Hopwood P, Stephens RJ. Depression in patients with lung cancer: Prevalence and risk factors derived from quality-of-life data. J Clin Oncol 2000; 18: 893–903.

    Google Scholar 

  37. Hopwood PH, Stephens RJ. Symptoms at presentation for treatment in patients with lung cancer: Implications for the evaluation of palliative treatment. Br J Cancer 1995; 71: 633–636.

    Google Scholar 

  38. Bailey AJ, Parmar MK, Stephens RJ. Patient-reported short-term and long-term physical and psychologic symptoms: results of the continuous hyperfractionated accelerated radiotherapy (CHART) randomized trial in non-small cell lung cancer. J Clin Oncol 1998; 16: 3082–3093.

    Google Scholar 

  39. Moinpour CM. Measuring quality of life: An emerging science. Semin Oncol 1994; 21(Suppl 10): 48–63.

    Google Scholar 

  40. Bleehen NM, Girling DJ, Machin D, Stephens RJ. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC) I: Survival and prognostic factors. Br J Cancer 1993; 68: 1150–1156.

    Google Scholar 

  41. Bleehen NM, Girling DJ, Machin D, Stephens RJ. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC) II: Quality of life. Br J Cancer 1993; 68: 1157–1166.

    Google Scholar 

  42. James LE, Gower NH, Rudd RM, et al. A randomised trial of low-dose/high-frequency chemotherapy as palliative treatment of poor-prognosis small-cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 1996; 73: 1563–1568.

    Google Scholar 

  43. MRC Lung Cancer Working Party. Randomised trial of four-drug vs. less intensive two-drug chemotherapy in palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Br J Cancer 1996; 73: 406–413.

    Google Scholar 

  44. Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR. Quality of life in lung cancer patients: As an important prognostic factor. Lung Cancer 2001; 31: 233–240.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Public Health, University of Glasgow, UK

    Ali Montazeri & James McEwen

  2. Department of Respiratory Medicine, Stobhill Hospital, UK

    Robert Milroy

  3. West of Scotland Cancer Surveillance Unit, Glasgow, UK

    David Hole & Charles R Gillis

Authors
  1. Ali Montazeri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Milroy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David Hole
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. James McEwen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Charles R Gillis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Montazeri, A., Milroy, R., Hole, D. et al. How quality of life data contribute to our understanding of cancer patients' experiences? A study of patients with lung cancer. Qual Life Res 12, 157–166 (2003). https://doi.org/10.1023/A:1022232624891

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1022232624891

Search

Navigation